Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems

NeuroRx

Volumn 2, Issue 1, 2005, Pages 54-62

  Tsuji, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; Drug delivery; Influx transport; Organic anions; Organic cations; Transporter

Indexed keywords

ALBUMIN; AZELASTINE; CAREBASTINE; CARRIER PROTEIN; CHLORPHENIRAMINE; CHOLINE; CLONIDINE; CYPROHEPTADINE; DIGOXIN; DIPHENHYDRAMINE; EBASTINE; EMEDASTINE; FENTANYL; GLUCOSE TRANSPORTER 1; HEMICHOLINIUM 3; HEXOSE; KETOTIFEN; LIPOSOME; MEPYRAMINE; MEVINOLIN; MONOCARBOXYLATE TRANSPORTER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX 26; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PRAVASTATIN; SIMVASTATIN; SODIUM GLUCOSE COTRANSPORTER 1; UNCLASSIFIED DRUG; VERAPAMIL; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; LIPOPHILICITY; MOLECULAR SIZE; NEUROTOXICITY; NONHUMAN; NUTRIENT; PHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER;

EID: 12344273724     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.1.54     Document Type: Article

References (87)

1. Smith QR, Stoll J Blood-brain barrier amino acid transport. In: Introduction to the blood-brain barrier (Pardridge WM, ed), pp 188-197. Cambridge, UK: Cambridge University Press, 1998.
2. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70:43-77, 1990.
3. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "ON-OFF" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 310:483-488, 1984.
4. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629-23632, 1998.
5. Mastroberardino L, Spindler B, Pfeiffer R, Skelly PJ, Loffing J, Shoemaker CB et al. Amino acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395:288-291, 1998.
6. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 12:96:12079-12084, 1999.
7. Boado RJ, Li JY, Pardridge WM. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J Neurochem 84:1322-1323, 2003.
8. Pineda M, Fernandez E, Torrents D, Estevez R, Lopez C, Camps M, et al. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 274:19738-19744, 1999.
9. +-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 274:19745-19751, 1999.
10. Kido Y, Tamai I, Uchino H, Sai Y, Suzuki F, Tsuji A. Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier. J Pharm Pharmcol 53:497-503, 2001.
11. Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 63:1481-1535, 1983.
12. Nishizaki T, Kammesheidt A, Sumikawa K, Asada T, Okada Y. A sodium- and energy-dependent glucose transporter with similarity to SGLT1-2 is expressed in bovine cortical vessels. Neurosci Res 22:13-22, 1995.
13. Kumagai AK, Dwyer KJ, Pardridge WM. Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. Biochim Biophys Acta 91:1193:24-30, 1994.
14. Halmos T, Santarromana M, Antonakis K, Scherman D. Synthesis of O-methylsulfonyl derivatives of D-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Carbohyd Res 299:15-21, 1997.
15. Negri L, Lattanzi R, Tabacco F, Scolaro B, Rocchi R. Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration. Br J Pharmacol 124:1516-1522, 1998.
16. Gerhart DZ, Enerson BE, Zhdankina OY, Leino RL, Drews LR. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am J Physiol (Lond) 273:E207-E213, 1997.
17. Kido Y, Tamai I, Okamoto M, Suzuki F, Tsuji A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier of rats using in vivo cultured cells and in vivo BUI studies. Pharm Res 17:55-62, 2000.
18. Oldendolf WH. Blood-brain barrier permeability of lactate. Eur Neurol 6:49-55, 1971.
19. Oldendolf WH. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. Am J Physiol (Lond) 224:1450-1453, 1973.
20. Nemoto EM, Severinghaus JW. Stereopecfic permeability of rat blood-brain barrier to lactic acid. Stroke 5:81-84, 1997.
21. Kang YS, Terasaki T, Tsuji A. Acidic drug transport in vivo through the blood-brain barrier: a role of the transport carrier for monocarboxylic acids. J Pharmacobiodyn 13:158-163, 1990.
22. Terasaki T, Kang YS, Ohnishi T, Tsuji A. In-vitro evidence for carrier-mediated uptake of acidic drugs by isolated bovine brain capillaries. J Pharm Pharmacol 43:172-176, 1991.
23. Terasaki T, Takakuwa S, Moritani S, Tsuji A. Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. J Pharmacol Exp Ther 258:932-937, 1991.
24. Enerson B, Drewes LR. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci 92:1531-1544, 2003.
25. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, et al. Immunohistochemical and functional characterization of pH-dependent intestinal absorption of organic weak acids by monocarboxylic acid transporter MCT1. J Pharm Pharmacol 51:113-1121, 1999.
26. Garcia CK, Goldstein JL, Oathak RK, Anderson RG, Brown MS. Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle. Cell 76:865-873, 1994.
27. Deguchi Y, Nozawa K, Yamada S, Yokoyama Y Kimura R. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. J Pharmacol Exp Ther 280:551-560, 1997.
28. Deguchi Y, Yokoyama Y, Sakamoto T, Hayashi H, Naito T, Yamada S, et al. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci 66:649-662, 2000.
29. Sun H, Dai H, Shaik N, Elmquist WE. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105, 2003.
30. Cornford EM, Diep CP, Pardridge WM. Blood-brain barrier transport of valproic acid. J Neurochem 44:1541-1550, 1985.
31. Adkison KDK, Shen DD. Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther 276:1189-1200, 1996.
32. Sekine T, Watanabe T, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526-18529, 1997.
33. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Eur J Physiol (Lond) 400:337-350, 2000.
34. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch-Eur J Physiol (Lond) 440:337-350, 2000.
35. Gao B, Stieger B, Now B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264, 1999.
36. Hagenbuch B, Gao B, Meier PJ. Transport of xenobiotics across the blood-bran barrier. News Physiol Sci 17:231-234, 2002.
37. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Sugiyama Y, Kanai K, Endou H. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675-13680, 1999.
38. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260, 2000.
39. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide OATP-B in comparison with liver-specific OATP-C. Pharm Res 18:1262-1269, 2001.
40. Gao B, Vavricha S, Huber RD, Meier PJ. Differential cellular localization of organic anion transporting polypeptides in human brain and retina. PharmConference, Abstract P12, Pontresina, Switzerland, 2003.
41. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703-708, 2003.
42. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438-445, 2004.
43. Tsuji A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 267:1085-1090, 1993.
44. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11:305-311, 1994.
45. Zhang L, Brett CM, GiacoMmini KM. Role of organic cation transporters in drug absorption and elimination. Annu Rev Pharmacol Toxicol 38:431-460, 1998.
46. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342-352, 1998.
47. Wu X, Kekuda R, Huang W, Fei Y-J, Leibach FH, Chen J, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776-32786, 1998.
48. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419:107-111, 1997.
49. Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, Shimane M, Tsuji A. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem 275:40064-40072, 2000.
50. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, et al. Molecular and functional identification of sodium ion-dependent high affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382, 1998.
51. Sekine T, Kusuhara H, Utsunomia-Tate N, Tsuda M, Sugiyama Y, Kanai Y, et al. Molecular cloning and characterization of high-affinity carnitine transporter from rat intestine. Biochem Biophys Res Commun 251:586-591, 1998.
52. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, et al. Primary systemic carnitine deficiency is caused by mutations in a sodium-ion dependent carnitine transporter OCTN2. Nat Genet 21:91-94, 1999.
53. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36:471-475, 2004.
54. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 289:768-773, 1999.
55. Wu X, Prasado PD, Leibach FH, Ganapathy V. cDNA sequence, transport function, and geneomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophy Res Commun 246:589-595, 1998.
56. Wu X, Huang W, Prasado PD, Seth P, Rajan DP, Leibach FH, et al. Functional characterization and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 290:1482-1492, 1999.
57. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291:778-784, 1999.
58. Ohashi R, Tamai I, Nezu J, Nikaido H, Hashimoto N, Oku A, et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 59:358-366, 2001.
59. Friedrich A, Prasasd PD, Freyer D, Ganapathy V, Brust P. Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier. Brain Res 968:69-79, 2003.
60. Inano A, Sai Y, Nikaido H, Hasimoto N, Asano M, Tsuji A. Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Dispos 24: 357-365, 2003.
61. 1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using carotid injection technique. Biol Pharm Bull 17:676-679, 1994.
62. 1-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures. Pharm Res 11:975-978, 1994.
63. 1-antagonists and lipophilic basic drugs. Pharm Res 11:1516-1518, 1994.
64. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871, 1999.
65. Vincent J, Liminana R, Meredith PA, Reid JL. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 26:497-502, 1998.
66. Matsuda M, Sakashita M, Mizuki Y, Yamaguchi T, Fujii T, Sekine Y. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys. Arzneim-Forsch/Drug Res 44:55-59, 1994.
67. Yamaguchi T, Hashizume T, Matsuda M, Sakashita M, Fujii T, Sekine Y, et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung 44:59-64, 1994.
68. 1-antagonist ebastine and its metabolite carebastine. J Drug Target 8:383-393, 2000.
69. Huwyler J, Fricker G, Torok M, Schneider M, Drewe J. Transport of clonidine across cultured brain microvessel endothelial cells. J Pharmacol Exp Ther 282:81-85, 1997.
70. Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 289: 1084-1089, 1999.
71. Suzuki T, Moriki Y, Goto H, Tomono K, Hanano M, Watanabe J. Investigation on the influx transport mechanism of pentazocine at the blood-brain barrier in rats using the carotid injection technique. Biol Pharm Bull 25:1351-1355, 2002.
72. Moriki Y, Suzuki T, Fukami T, Hanano M, Tomono K, Watanabe J. Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method. Biol Pharm Bull 27:932-935, 2004.
73. Banks WA, Audus K, Davis TP. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 13:1289-1294, 1992.
74. Begley DJ. The blood-brain barrier: principle for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48:136-146, 1996.
75. Zlokovic, BV, Lipovac MN, Begley DJ, Davson H, Rakic L. Slow penetration of thyrotropine-releasing hormone across the blood-brain barrier of an in situ perfused guinea pig brain. J Neurochem 51:252-257, 1988.
76. Zlokovic BV, Hyman S, McComb JG, Lipovac MN, Tang G, Davson H. Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim Biophys Acta 1025:191-198, 1990.
77. Barrera CM, Kastin AJ, Banks WA. D-[Ala1]-peptide T-amide is transported from blood to brain by saturable system. Brain Res Bull 19:629-633, 1987.
78. Wilson JF. Low permeability of the blood-brain barrier to nanomolar concentrations of immunoreactive α-melanotropin. Psychopharmacol 96:262-266, 1988.
79. 125I-N-Tyr-δ sleeping peptide crosses the blood-brain barrier by a noncompetitive mechanism. Brain Res 301:201-207, 1984.
80. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79, 2000.
81. Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N. Evidence for carrier-mediated transport for glutathione across the blood-brain barrier in the rat. Am J Physiol (Lond) 259:E1-E10, 1990.
82. Kannan R, Kuhlenkamp JF, Ookhtens M, Kaplowitz N. Transport of glutathione at the blood-brain barrier of the rat: inhibition by glutathione analogues and age-dependence. J Pharmacol Exp Ther 263:964-970, 1992.
83. Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplowitz N, Kannan R. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201:402-408, 1994.
84. Kannan R, Yi JR, Tang D, Li Y, Zlokovic BV, Kaplowitz N. Evidence for the existence of a sodium-dependent glutathione (GSH) transporter. Expression of bovine brain capillary mRNA and size fractions in Xenopus laevis oocytes and dissociation from γ-glutamyltranspeptidase and facilitative GSH transporters. J Biol Chem 271:9754-9758, 1996.
85. Kannan R, Mittut A, Bao Y, Tsuruo T, Kaplowitz N. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. J Neurochem 73:390-399, 1999.
86. Toyobuku H, Sai Y, Kagami T, Tamai I, Tsuji A. Delivery of peptide drugs to the brain by adenovirus-mediated heterologous expression of human oligopeptide transporter at the blood-brain barrier. J Pharmacol Exp Ther 305:40-47, 2003.
87. Schlapbach R, Fontana, A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. Biochim Biophys Acta 1359:174-180, 1997.